Unlabelled: We established a protocol to determine the serum prostate-specific antigen (PSA) in male donors of 50 years or older, and to histologically examine the prostate glands. From January 1997 to December 2002 we analysed serum PSA in 51 cases, of which it was normal in 34 and high in 17. Prostate glands were examined histologically in 13 of the high PSA cases. Donors were classified according to the PSA level and histology: donors with high PSA values and adenocarcinoma or high-grade PIN (group A, n=6); donors with elevated PSA but no malignancy (group B, n=7); and donors with normal PSA (group C, n=34). The ages, days in hospital, and causes of death were similar among the 3 groups. The levels of PSA were significantly higher among group A than group B or group C, but were similar between group B and C. The list of transplanted organs is as follows: 5 organs of group A; 8 organs of group B; and 59 organs of group C.
Conclusions: High PSA levels seem show 2 patterns: (1) small increases of PSA related to donors with no prostate cancer, and (2) high levels of PSA related to the presence of prostate cancer, as is the case in the general population. The incidence of prostate cancer in overall male donors was 3.1%. Due to this high incidence, we believe it is important to determine PSA levels to diagnose prostate cancer in older donors. A separate consideration is what to do with the organs of those donors.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0041-1345(03)00693-6 | DOI Listing |
J Clin Oncol
January 2025
Fred Saad, MD, University of Montreal, Montreal, QC, Canada; Egils Vjaters, MD, P. Stradinš Clinical University Hospital, Riga, Latvia; Isabella Testa, MD, Bayer S.p.A, Milan, Italy; and Kunhi Parambath Haresh, MD, All India Institute of Medical Sciences, New Delhi, India.
J Clin Oncol
January 2025
Abhenil Mittal, MD, DM, MBBS and Geordie Linford, MD, MSc, BSc, Department of Oncology, Northeast Cancer Center, Health Sciences North, Sudbury, ON, Canada, Division of Clinical Sciences, Northern Ontario School of Medicine, ON, Canada; and Bishal Gyawali, MD, PhD, FASCO, Department of Oncology, Queen's University, Kingston, ON, Canada, Department of Public Health Sciences, Queen's University, Kingston, ON, Canada, Division of Cancer Care and Epidemiology, Queen's University, Kingston, ON, Canada.
PLoS One
January 2025
UVSQ, Inserm, Gustave Roussy, CESP, Université Paris-Saclay, Villejuif, France.
Background: Prostate cancer remains the most frequent cancer among men, representing a significant health burden. Despite its high morbidity and mortality rates, the etiology of prostate cancer remains relatively unknown, with only non-modifiable established risk factors. Chronic inflammation has emerged as a potential factor in prostate carcinogenesis.
View Article and Find Full Text PDFJ Med Chem
January 2025
Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China.
Precise surgical resection of prostate cancer (PCa) is a significant clinical challenge due to the impact of positive surgical margins on postoperative outcomes. Fluorescence-guided surgery (FGS) enables real-time tumor visualization using fluorescent probes. In this study, we synthesized and evaluated an indocyanine green (ICG)-based PSMA-targeted near-infrared probe, , for intraoperative imaging of PCa lesions.
View Article and Find Full Text PDFJ Zhejiang Univ Sci B
January 2025
Department of Orthopedics, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.
Prostate cancer is the second most common cancer in men, accounting for 14.1% of new cancer cases in 2020. The aggressiveness of prostate cancer is highly variable, depending on its grade and stage at the time of diagnosis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!